{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:02:59Z","timestamp":1792843379357,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,1]],"date-time":"2027-05-01T00:00:00Z","timestamp":1809129600000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","hpbonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["HPB"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.hpb.2026.01.011","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:26:47Z","timestamp":1769732807000},"page":"666-675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neoadjuvant chemotherapy versus upfront surgery for perihilar cholangiocarcinoma: a propensity score matching analysis"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3675-7841","authenticated-orcid":false,"given":"Keita","family":"Sonoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5840-8901","authenticated-orcid":false,"given":"Yuta","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naokazu","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kisyo","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Hayatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0366-8367","authenticated-orcid":false,"given":"Kiminori","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3733-7411","authenticated-orcid":false,"given":"Ryo","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Kitago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4990-0419","authenticated-orcid":false,"given":"Yasushi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutaro","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0335-3912","authenticated-orcid":false,"given":"Masayuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4284-2989","authenticated-orcid":false,"given":"Kohei","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Kawachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hpb.2026.01.011_bib1","first-page":"2021","article-title":"Nationwide treatment and outcomes of perihilar cholangiocarcinoma","volume":"41","author":"van Keulen","year":"1945","journal-title":"Liver Int"},{"key":"10.1016\/j.hpb.2026.01.011_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.14701\/ahbps.23-170","article-title":"Practice guidelines for managing extrahepatic biliary tract cancers","volume":"28","author":"Kim","year":"2024","journal-title":"Ann Hepato-Biliary-Pancreat Surg"},{"key":"10.1016\/j.hpb.2026.01.011_bib3","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00000658-199604000-00007","article-title":"Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma","volume":"223","author":"Su","year":"1996","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2026.01.011_bib4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/00000658-199911000-00008","article-title":"Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection","volume":"230","author":"Kosuge","year":"1999","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2026.01.011_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00000658-200110000-00010","article-title":"Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma","volume":"234","author":"Jarnagin","year":"2001","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2026.01.011_bib6","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/cncr.11699","article-title":"Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies","volume":"98","author":"Jarnagin","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.hpb.2026.01.011_bib7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.sla.0000179678.13285.fa","article-title":"Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma","volume":"242","author":"Rea","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2026.01.011_bib8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2026.01.011_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/bjs.6788","article-title":"Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma","volume":"97","author":"Kobayashi","year":"2010","journal-title":"Br J Surg"},{"key":"10.1016\/j.hpb.2026.01.011_bib10","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1186\/s12885-020-07185-6","article-title":"A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01)","volume":"20","author":"Itano","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hpb.2026.01.011_bib11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.hpb.2026.01.011_bib12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hpb.2026.01.011_bib13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/SLA.0000000000002865","article-title":"A prospective, randomized phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary oncology group","volume":"270","author":"Kobayashi","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2026.01.011_bib14","first-page":"2019","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"1950","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hpb.2026.01.011_bib15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hpb.2026.01.011_bib16","doi-asserted-by":"crossref","first-page":"106994","DOI":"10.1016\/j.ejso.2023.106994","article-title":"Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection","volume":"49","author":"Hassan","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.hpb.2026.01.011_bib17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi","year":"2023","journal-title":"Lancet"},{"issue":"suppl","key":"10.1016\/j.hpb.2026.01.011_bib18","article-title":"Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas","volume":"39","author":"Katz","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hpb.2026.01.011_bib19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hpb.2026.01.011_bib20","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12957-024-03609-w","article-title":"Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study","volume":"22","author":"Shimane","year":"2024","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.hpb.2026.01.011_bib21","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3390\/jcm12072654","article-title":"Neoadjuvant therapy for extrahepatic biliary tract cancer: a propensity score-matched survival analysis","volume":"12","author":"Toyoda","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.hpb.2026.01.011_bib22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s12885-020-06895-1","article-title":"Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status","volume":"20","author":"Kuriyama","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hpb.2026.01.011_bib23","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1245\/s10434-021-11206-4","article-title":"Impact of gemcitabine plus S1 neoadjuvant chemotherapy on borderline resectable perihilar cholangiocarcinoma","volume":"29","author":"Matsuyama","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2026.01.011_bib24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hpb.2026.01.011_bib25","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Do-Youn","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.hpb.2026.01.011_bib26","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.hpb.2026.01.011_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J Hepato-Biliary-Pancreatic Sci"},{"key":"10.1016\/j.hpb.2026.01.011_bib28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/cancers15010294","article-title":"Pathological response predicts survival after pancreatectomy following neoadjuvant FOLFIRINOX for pancreatic cancer","volume":"15","author":"Jeon","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.hpb.2026.01.011_bib29","doi-asserted-by":"crossref","first-page":"107117","DOI":"10.1016\/j.ejso.2023.107117","article-title":"National consensus on a new resectability classification for perihilar cholangiocarcinoma - a modified Delphi method","volume":"51","author":"Nooijen","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.hpb.2026.01.011_bib30","doi-asserted-by":"crossref","first-page":"107117","DOI":"10.1016\/j.ejso.2023.107117","article-title":"National consensus on a new resectability classification for perihilar cholangiocarcinoma - a modified Delphi method","volume":"51","author":"Nooijen","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.hpb.2026.01.011_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3348\/jksr.2024.0055","article-title":"Preoperative imaging assessment and staging of perihilar cholangiocarcinoma: tips and pitfalls","volume":"86","author":"Yong","year":"2025","journal-title":"J Korean Soc Radiol"},{"key":"10.1016\/j.hpb.2026.01.011_bib32","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1007\/s00268-018-4654-2","article-title":"Impact of biliary drainage on multidetector-row computed tomography on R0 resection of perihilar cholangiocarcinoma","volume":"42","author":"Hosokawa","year":"2018","journal-title":"World J Surg"},{"key":"10.1016\/j.hpb.2026.01.011_bib33","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"}],"container-title":["HPB"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X26000122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X26000122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:53:35Z","timestamp":1777672415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1365182X26000122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1365182X26000122"],"URL":"https:\/\/doi.org\/10.1016\/j.hpb.2026.01.011","relation":{},"ISSN":["1365-182X"],"issn-type":[{"value":"1365-182X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant chemotherapy versus upfront surgery for perihilar cholangiocarcinoma: a propensity score matching analysis","name":"articletitle","label":"Article Title"},{"value":"HPB","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpb.2026.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}